Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 4/2021

Open Access 01-04-2021 | Literatur kommentiert

Kurative Strahlentherapie von Oligometastasen: Langzeitergebnisse der SABR-COMET-Studie

Author: Prof. Dr. med. Jürgen Dunst

Published in: Strahlentherapie und Onkologie | Issue 4/2021

Login to get access

Auszug

Vor etwa 25 Jahren wurde erstmals durch die Radioonkologen Hellman und Weichselbaum die Hypothese der Oligometastasierung formuliert [2]. Darin wird postuliert, dass Patienten mit wenigen Metastasen (also einem frühen Stadium IV einer Erkrankung) nicht nur eine makroskopische, sondern vermutlich auch eine mikroskopische Tumorlast haben, die etwa einem Stadium III oder sogar II entspricht. Die Idee war, diese Patienten dann auch wie ein Stadium III zu behandeln, also mit einer „kurativen“ lokalen Therapie und „adjuvanten“ medikamentösen Therapie. …
Literature
1.
Gomez DR, Tang C, Zhang J et al (2019) Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 37:1558–1565CrossRef
2.
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10CrossRef
3.
Iyengar P, Wardak Z, Gerber DE et al (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 4:e173501CrossRef
4.
Lewis SL, Porceddu S, Nakamura N et al (2017) Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of 1000radiation oncologists. Am J Clin Oncol 40:418–422CrossRef
5.
Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective,randomized, multicenter phase II trial. J Clin Oncol 36:446–453CrossRef
6.
Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers(SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051–2058CrossRef
7.
Palma DA, Olson R, Harrow S et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastaticcancers: long-term results of the SABR-COMETphase II randomized trial. J Clin Oncol 38:2830–2838CrossRef
8.
Phillips R, Lim SJ, Shi WY et al (2019) Primary outcomes of a phase II randomized trial of observation versus stereotactic ablative radiation for oligometastaticprostate cancer (ORIOLE). Int J Radiat Oncol Biol Phys 105:681CrossRef
9.
Thelen WSME, Peulen HMU, Lalezari F et al (2019) Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non—small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol 5:1276–1282CrossRef
Metadata
Title
Kurative Strahlentherapie von Oligometastasen: Langzeitergebnisse der SABR-COMET-Studie
Author
Prof. Dr. med. Jürgen Dunst
Publication date
01-04-2021
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 4/2021
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-021-01745-w

Other articles of this Issue 4/2021

Strahlentherapie und Onkologie 4/2021 Go to the issue

Original Article

Is prone free breathing better than supine deep inspiration breath-hold for left whole-breast radiotherapy? A dosimetric analysis

Review Article

Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward

Original Article

The role of a knowledge based dose–volume histogram predictive model in the optimisation of intensity-modulated proton plans for hepatocellular carcinoma patients

Original Article

Synergistic effect of PAF inhibition and X-ray irradiation in non-small cell lung cancer cells

Literatur kommentiert

Sollen fortgeschrittene Magenkarzinome zukünftig nur mehr laparoskopisch operiert werden?

Original Article

Quality of life and fatigue before and after radiotherapy in breast cancer patients